Institution · Nebraska Cancer Specialists

Most cited papers from Nebraska Cancer Specialists

Nebraska Cancer Specialists

What are the most cited papers from Nebraska Cancer Specialists?

The most cited paper from Nebraska Cancer Specialists is "Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies" (Ranjana H. Advani, Joseph J. Buggy, Jeff Porter Sharman et al., 2012), with 1,129 citations. Next come "Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial" (569) and "Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134" (474).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 33 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies Ranjana H. Advani, Joseph J. Buggy, Jeff Porter Sharman et al. · Journal of Clinical Oncology Open access	9 Oct 2012	1,129
2	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Arlene Chan et al. · The Lancet Oncology	12 Feb 2016	569
3	Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134 Michael B. Atkins et al. · Journal of Clinical Oncology Open access	27 Sep 2022	474
4	IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection Jason Beiko, Dima Suki, Kenneth R. Hess et al. · Neuro-Oncology Open access	4 Dec 2013	470
5	Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline W. Kimryn Rathmell, R. Bryan Rumble, Peter J. Van Veldhuizen et al. · Journal of Clinical Oncology	21 Jun 2022	351
6	Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma Neil D. Gross et al. · New England Journal of Medicine Open access	12 Sep 2022	334
7	Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours Cheryl A. London et al. · Veterinary and Comparative Oncology Open access	Jun 2011	231
8	Collagen I Promotes Metastasis in Pancreatic Cancer by Activating c-Jun NH2-Terminal Kinase 1 and Up-regulating N-Cadherin Expression Yasushi Shintani, Michael Anthony Hollingsworth, Margaret J. Wheelock et al. · Cancer Research Open access	15 Dec 2006	230
9	Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial David Robert Spigel, P. Townley, David Michael Waterhouse et al. · Journal of Clinical Oncology Open access	19 Apr 2011	227
10	American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer J. Douglas Rizzo, Melissa C. Brouwers, Patricia A. Hurley et al. · Blood	26 Oct 2010	207
11	5-Lipoxygenase and Leukotriene B4 Receptor Are Expressed in Human Pancreatic Cancers But Not in Pancreatic Ducts in Normal Tissue René Hennig, Xianzhong Ding, Weigang Tong et al. · American Journal Of Pathology Open access	Aug 2002	190
12	Hereditary nonpolyposis colorectal cancer (lynch syndromes I and II). II. Biomarker studies Henry T. Lynch, Guy S. Schuelke, William J. Kimberling et al. · Cancer Open access	15 Aug 1985	169
13	Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial Charu Aggarwal et al. · Journal for ImmunoTherapy of Cancer Open access	Apr 2022	151
14	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer Samuel Ray Denmeade et al. · Journal of Clinical Oncology Open access	22 Feb 2021	144
15	Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor Scott M. Schuetze, Vanessa Bolejack, Edwin Choy et al. · Cancer Open access	3 Oct 2016	138
16	Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial Nicholas J. Robert, Mansoor Noorali Saleh, Devchand Paul et al. · Clinical Breast Cancer Open access	Apr 2011	119
17	Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study Marwan Fakih et al. · EClinicalMedicine Open access	Apr 2023	114
18	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes Matthew D. Galsky et al. · European Urology	13 Dec 2017	114
19	Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study Neil D. Gross et al. · The Lancet Oncology	21 Oct 2023	109
20	Safety and Efficacy of Nivolumab in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study Nicholas J. Vogelzang et al. · Clinical Genitourinary Cancer Open access	16 May 2020	107
21	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma Ajjai Shivaram Alva et al. · Cancer Immunology Immunotherapy Open access	6 Oct 2016	105
22	Facilitation of radiotherapeutic error by computerized record and verify systems Gregory Patton, David K. Gaffney, John Moeller · International Journal of Radiation OncologyBiologyPhysics	23 Apr 2003	103
23	Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide Dana E. Rathkopf et al. · Annals of Oncology Open access	Jun 2017	100
24	Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes Sheri Skerget et al. · Nature Genetics Open access129 authors	19 Aug 2024	94
25	Replication protein A, the laxative that keeps DNA regular: The importance of RPA phosphorylation in maintaining genome stability Brendan M. Byrne, Greg G. Oakley · Seminars in Cell and Developmental Biology	13 Nov 2018	91
26	Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone Dana E. Rathkopf, Emmanuel S. Antonarakis, Neal D. Shore et al. · Clinical Cancer Research Open access	17 Feb 2017	86
27	Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia John C. Byrd, Joseph Michael Flynn, Thomas J. Kipps et al. · Blood Open access	16 Oct 2015	86
28	Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study Shirish M. Gadgeel, James P. Stevenson, Corey Jay Langer et al. · Lung Cancer Open access	25 Aug 2018	84
29	Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma Danny Rischin et al. · New England Journal of Medicine	31 May 2025	82
30	Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis Mashaal Dhir, ELIZABETH R. LYDEN, Lynette M. Smith et al. · HPB ReviewOpen access	19 Jun 2012	81
31	Identification of a Novel, Recurrent SLC44A1‐PRKCA Fusion in Papillary Glioneuronal Tumor Julia A. Bridge, Xiao‐qiong Liu, János Sümegi et al. · Brain Pathology Open access	22 Jun 2012	81
32	A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma Tycel Jovelle Phillips, Paul M. Barr, Steven I. Park et al. · Investigational New Drugs Open access	22 Aug 2018	78
33	Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma Nicholas Di Bella, Raymond Taetle, Kathryn S. Kolibaba et al. · Blood	20 Nov 2009	77
34	A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy Sarah Ann Weiss, Mario Sznol, Montaser F. Shaheen et al. · Clinical Cancer Research Open access	3 Aug 2023	73
35	Survival trends in mantle cell lymphoma in the United States over 16 years 1992–2007 Rekha Chandran, Stuart K. Gardiner, M. Simon et al. · Leukemia & lymphoma/Leukemia and lymphoma	13 Jan 2012	72
36	DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2) Vince Bertucci, Nowell J. Solish, Joely Kaufman‐Janette et al. · Journal of the American Academy of Dermatology Open access	29 Nov 2019	70
37	Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma Rubén Niesvizky et al. · Leukemia & lymphoma/Leukemia and lymphoma	27 Mar 2015	66
38	Can pregabalin prevent paclitaxel-associated neuropathy?—An ACCRU pilot trial Shivani S. Shinde, Drew K. Seisler, Gamini S. Soori et al. · Supportive Care in Cancer	8 Jul 2015	65
39	Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer Guru Sonpavde, Ana Maria Aparicio, Feng Zhan et al. · Urologic Oncology Seminars and Original Investigations	7 Dec 2009	64
40	Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis Andrea P. Espejo Freire, Andrew Elliott, Andrew Eric Rosenberg et al. · Cancers Open access	26 Sep 2021	61
41	Clavicular Fractures Following Coracoclavicular Ligament Reconstruction with Tendon Graft Kimberly A. Turman, Chealon D. Miller, Mark D. Miller · Journal of Bone and Joint Surgery	Jun 2010	59
42	A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer Benjamin Philip Levy, Alexander I. Spira, Daniel Jacob Becker et al. · Journal of Thoracic Oncology Open access	12 Jun 2014	53
43	Holy Basil leaf extract decreases tumorigenicity and metastasis of aggressive human pancreatic cancer cells in vitro and in vivo: Potential role in therapy Tomohiro Shimizu, María P. Torres, Subhankar Chakraborty et al. · Cancer Letters Open access	21 Mar 2013	49
44	The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study Nathan Hale Fowler, Jeff Porte Sharman, Sonali M. Smith et al. · Blood	19 Nov 2010	48
45	Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry Mayer Fishman, Janice P. Dutcher, Joseph I. Clark et al. · Journal for ImmunoTherapy of Cancer Open access	27 Mar 2019	47
46	LBA6 Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition) S.T. Tagawa, O. Sartor, J.M. Piulats et al. · Annals of Oncology Open access	Sep 2025	45
47	Incidence and Prognostic Significance of Second Primary Cancers in Renal Cell Carcinoma Subhankar Chakraborty, Stefano Tarantolo, Surinder K. Batra et al. · American Journal of Clinical Oncology Open access	22 Mar 2012	44
48	Chemotherapy options in castration-resistant prostate cancer R. Hauke, Benjamin A. Teply · Indian Journal of Urology Open access	2016	42
49	A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma Daniel W. Bowles, Mark D. Kochenderfer, Allen Lee Cohn et al. · Clinical Colorectal Cancer	Apr 2016	42
50	An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer Allen Lee Cohn, Grace Shumaker, Pankaj Khandelwal et al. · Clinical Colorectal Cancer	26 May 2011	40

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.